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Abstract
We have previously shown that Annexin A8 (ANXA8) is strongly associated with the basal-
like subgroup of breast cancers, including BRCA1-associated breast cancers, and poor
prognosis; while in the mouse mammary gland AnxA8mRNA is expressed in low-prolifer-
ative isolated pubertal mouse mammary ductal epithelium and after enforced involution, but
not in isolated highly proliferative terminal end buds (TEB) or during pregnancy. To better
understand ANXA8’s association with this breast cancer subgroup we established
ANXA8’s cellular distribution in the mammary gland and ANXA8’s effect on cell proliferation.
We show that ANXA8 expression in the mouse mammary gland was strong during pre-pu-
berty before the expansion of the rudimentary ductal network and was limited to a distinct
subpopulation of ductal luminal epithelial cells but was not detected in TEB or in alveoli dur-
ing pregnancy. Similarly, during late involution its expression was found in the surviving
ductal epithelium, but not in the apoptotic alveoli. Double-immunofluorescence (IF) showed
that ANXA8 positive (+ve) cells were ER-alpha negative (−ve) and mostly quiescent, as de-
fined by lack of Ki67 expression during puberty and mid-pregnancy, but not terminally differ-
entiated with*15% of ANXA8 +ve cells re-entering the cell cycle at the start of pregnancy
(day 4.5). RT-PCR on RNA from FACS-sorted cells and double-IF showed that ANXA8+ve
cells were a subpopulation of c-kit +ve luminal progenitor cells, which have recently been
identified as the cells of origin of basal-like breast cancers. Over expression of ANXA8 in
the mammary epithelial cell line Kim-2 led to a G0/G1 arrest and suppressed Ki67 expres-
sion, indicating cell cycle exit. Our data therefore identify ANXA8 as a potential mediator of
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quiescence in the normal mouse mammary ductal epithelium, while its expression in basal-
like breast cancers may be linked to ANXA8’s association with their specific cells of origin.
Introduction
Annexins form a superfamily of calcium-dependent lipid-binding proteins broadly distributed
throughout all eukaryotic phyla and even some bacteria and archea. These proteins feature
unique homologous repeats that contain the calcium and lipid binding sites. However, their
calcium-dependent lipid-binding ability is not a universal feature of annexins since some of
them have partially or completely lost their type 2 calcium binding sites through evolutionary
divergence [1]. This patterned structural diversity corresponds to a functional adaptation char-
acteristic of individual subfamilies that ranges from membrane and cytoskeletal organisation to
the regulation of membrane traffic and signalling. Annexins have also been shown to act as ex-
tracellular anti-inflammatory and anti-coagulant factors as cell surface proteins, and some
have even been proposed to have nuclear roles [2–5]. They are further involved in phagocytosis
as well as endo- and exocytosis (for reviews see [6–9]). Most initial studies have focused on
their calcium-dependent membrane-binding properties but these may not be universal nor es-
sential features for their action. Function-oriented studies have described annexins involved in
cell growth and proliferation [10–12] and alterations of their expression have been associated
with cancer subtypes and other diseases [13–16].
ANXA8 is one of the least characterised members of the annexin superfamily. ANXA8 was
first described as an inhibitor of phospholipase A2 and as a blood coagulation factor (VAC-β)
because of its structural similarity to VAC-α (ANXA5, lipocortin V) [17]. It was later found to
be specifically over expressed in acute promyelocytic leukaemia (APL) where it was repressible
by all-trans retinoic acid (ATRA) [18–21]. Deregulation of ANXA8 has since then been found
in several other malignancies, including infiltrating adenocarcinomas of the pancreas [22],
cholangiocarcinoma [23], malignant pleural mesothelioma [24], melanoma [25], squamous
carcinoma of the uterine cervix [26], esophageal adenocarcinoma and Barrett’s metaplasia
[27]. Perou et al. (2000) identified AnxA8 by microarray analysis as part of an RNA signature
for a subgroup of breast cancers with poor prognosis they called basal-like breast cancers be-
cause of their expression of basal cell associated cytokeratins (CK) 5 and 17 [28]. Our own
work has previously established that ANXA8 protein is not detected in the majority of breast
cancers but in a distinct subset of CK5 positive, oestrogen receptor (ER) α and progesterone re-
ceptor (PgR) negative breast cancers with poor prognosis and in a high percentage of BRCA1-
associated cancers [29], confirming the RNA profiles by Perou et al. [28] and Sorlie et al. [30].
ANXA8 has been linked to the formation of endosomes and epidermal growth factor recep-
tor (EGFR) turnover in Hela cells [31], and is required for efficient cell surface presentation of
CD63 and P-selectin to allow leukocyte recruitment by activated endothelial cells [32]. Other
studies identified ANXA8 as a target for p53-activated DNA damage response after treatment
with adriamycin/doxorubicin of mouse embryonic fibroblasts [33] or when p53 was over ex-
pressed in Saos2 cells [34]. However its biological function in the mammary gland is
still unknown.
We have previously shown that Anxa8mRNA was up-regulated during mouse mammary
gland involution [29], a multi-step process in which the alveolar epithelium regresses by pro-
grammed cell death to a near pre-pregnant morphology [27, 32]. In the pubertal gland, Anxa8
mRNA was found in enzymatically isolated epithelial ducts but not in terminal end buds [29].
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In general, Anxa8mRNA abundance was highest during periods of widespread cell death or
low proliferation. To get a better understanding of ANXA8’s role during mammary gland de-
velopment we aimed to determine its cellular distribution at different developmental time
points, to assess its association with different epithelial subpopulations, and to study the effect
of ANXA8 expression in vitro.
Here we show for the first time that ANXA8 is expressed in a distinct quiescent subpopula-
tion of ERα−ve cells of the ductal mammary epithelium during puberty and early pregnancy,
but not in proliferating TEB or alveoli. During late involution, ANXA8 was only detected in
the surviving epithelium, but not in the apoptotic cells. qRT-PCR using mRNA from FACS-
sorted cells showed that AnxA8 was strongly associated with c-kit+ve/ERα−ve luminal progen-
itor cells (CD45−, CD24+/high, Sca1−, cd49f−, c-kit+), and triple-IF staining associated ANXA8
expression with a transiently quiescent subpopulation of the ductal luminal epithelium. Over
expression in the mammary epithelial cell line KIM-2 altered the cell morphology and removed
these cells from the cell cycle. Our data therefore strongly link ANXA8 to a subpopulation of c-
kit+ve/ERα−ve ductal luminal epithelial progenitor cells and links ANXA8 function with cellu-
lar quiescence in the mammary epithelium. As this cell population was recently identified as
the likely cells of origin for basal-like breast cancers, ANXA8’s expression in this cancer sub-
group may therefore be a consequence of their cells of origin and thus a useful diagnostic
marker.
Materials and Methods
Ethics statement
All animal work was conducted under project licence numbers PPL 60/3712 and PPL60/4181
in accordance with accepted standards of humane animal care and according to the UK Ani-
mals (Scientific Procedures) Act 1986 and the EU directive 2010 in dedicated facilities proac-
tive in environmental enrichment. Ethical approval granted by University of Glasgow.
Mammary gland preparation
The 4th (inguinal) mammary glands were dissected and used for immunohistochemical stain-
ing or RNA extraction as described previously [35]. Balb/C mice were used unless
stated otherwise.
Cell Culture
KIM-2 cells were generated in the laboratory of C. Watson [36] and were maintained as previ-
ously described [36].
Anxa8 cloning into pRTS1
Anxa8 cDNA was cloned into the pRTS1 episomal vector [37], a generous gift from Prof Born-
kamm, before generation of KIM-2 cell lines that express Anxa8 under the control of doxycy-
cline. To generate the pRTS1:Anxa8 construct, the mouse cDNA of Anxa8 was cut from the
IMAGE clone 5322310 using the restriction enzymes XhoI and EcoRV and ligated into the
pUC19-SfiI vector using the XhoI and EcoRV restriction sites. The resulting construct was di-
gested with Sfi1 and the cDNA fragment ligated into the Sfi1 sites of the pRTS1 vector. Positive
clones were confirmed by sequencing. KIM-2 cells were transfected using FuGene 6 (Roche
Applied Science, Burgess Hill, UK) according to manufacturer’s instructions with pRTS1:
AnxA8 and pRTS1 constructs and transfected cells were selected as pools using 250μg/ml of
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hygromycin (Calbiochem, Merck KG, Darmstadt, Germany) to establish Kim2A8 and
Kim2RTS cell lines.
Growth assay
Cells were plated in 24 well plates in triplicate and allowed to grow overnight before the addi-
tion of 100ng/ml doxycycline (Sigma-Aldrich, Gillingham, UK) at day 0. After washing the
cells twice in PBS, protein lysates were prepared every 24 hours in Triton X-100 lysis buffer
(20mM Tris pH 7.4, 250mMNaCl, 1% Triton X-100) plus Complete Mini Inhibitor mix
(Roche Applied Science) and Protein Phosphatase Inhibitor Cocktail 2 (Sigma-Aldrich), and
stored at −20°C. The protein concentration was measured using a BCA Protein Assay (Pierce,
Thermo Fisher Scientific Inc, Rockford, USA).
BrdU/EdU incorporation assay
Proliferation was measured using a Cell Proliferation ELISA, BrdU colourimetric kit (Roche
Applied Science) in a 96 well format after 48 hours of doxycycline treatment (100ng/ml).
For in vivo EdU incorporation: C57Bl/6 mice were stud mated and allowed to lactate with
standardized litter sizes of 5–6 for 7 days at which time forced involution was induced. The fe-
males were injected intra-peritoneally with 0.2ml of 5mg/ml EdU 2hr prior to sacrifice on day
4 after forced involution. For pre-pubertal samples EdU was injected in 3-week old females
as above.
Colony formation assay
Between 250 and 300 cells were seeded each in 10cm culture dishes in medium containing no
doxycyline or 100ng/ml doxycycline. Cells were allowed to adhere and grow for 2 weeks, fixed
with methanol, air dried and stained using Giemsa’s staining solution (BDH Laboratory Sup-
plies, Merck Ltd., Lutterworth, UK). Pictures of the plates were taken using a digital camera
and the number of colonies was quantified using ImageJ software.
Cell cycle analysis by flow cytometry
Cells were grown in 6-well plates and treated with 100ng/ml doxycycline for 48 hours, trypsi-
nized with Trypsin-EDTA, and collected together with any floating cells in the culture media.
The cells were resuspended in 0.5ml PBS and fixed in 5ml 100% ice-cold methanol while vor-
texing. Cells were incubated for two hours at 4°C. After brief centrifugation, the methanol was
removed and cells incubated in 400μl PI solution (50μg/ml propidium iodide, 50μg/ml RNAse
A in PBS) for 30min before analysis on a BD FACSCanto II Flow Cytometer. Cyflogic software
was used for analysis.
Antibody production
The mouse Anxa8 coding region was amplified by PCR using the primers A8-5’ (aatagaatt-
caatggcctggtggaaagcc) and A8-3’ (cgatctcgagtcagaggtcagtgcccac) and the IMAGE clone
5322310 as template. The PCR fragment was digested with EcoR1 and XhoI, cloned into
pET302NT His vector (Invitrogen, Paisley, UK) digested with the same restriction sites and se-
quenced to verify that the 6xHis tag was in frame and the Anxa8 sequence was correct. This
construct was used to produce ANXA8 protein in BL21 cells and the protein was purified using
the TALONMetal Affinity Resin and Buffers (Clontech, Takara Bio Europe, Saint-Germain-
en-Laye, France). After dialysis against PBS to remove imidazole, the purified protein was used
to immunize two rabbits at EUROGENTEC (Fawley, Southampton, Hampshire, UK), using
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their standard protocol. The antiserum was affinity purified using recombinant His-tagged
ANXA8 protein immobilized in a column generated using an AminoLink Plus Immobilisation
Kit (Pierce). The antibodies were eluted from the column using 100mM glycine pH 2.5 and im-
mediately neutralized by addition of 1/10 of the elution volume of 1M Tris. The specificity of
the antibody was tested by western blot.
Immunofluorescence and Immunohistochemistry
Cells were grown on eight-well chamber slides for the indicated times and fixed in 4% parafor-
maldehyde for 20 min at RT. After extensive washes with PBS, cells were incubated for 10 min
in 50mM ammonium chloride followed by incubation for 10 min in 20mM glycine. Cells were
incubated for 30–45 min in blocking solution (2.5% horse serum in PBS, 0.3% Triton X-100) to
prevent nonspecific binding. The primary and secondary antibodies were diluted in blocking
solution and antibody incubations were carried out at RT for 45–60 min. Washes were done
with 0.1% Triton X-100 in PBS. Cells were finally washed in PBS before mounting the slides
using Prolong Gold Antifade Reagent with DAPI (Molecular Probes, Invitrogen). Images were
taken using an Olympus IX51 inverted microscope using a F-View camera and Cell^P 2.5 soft-
ware (Olympus UK Ltd, Southend-on-Sea, Essex, UK). ImageJ software was used for
image analysis.
For immunofluorescence (IF) on paraffin-embedded tissue, the sections were dewaxed in
xylene and rehydrated through an alcohol gradient. Antigen retrieval was performed in 10 mM
EDTA pH 8.0, sections were treated with Image-iT FX (Molecular Probes) for 30 min at room
temperature and blocked with 2.5% horse serum in TBS-0.01% Tween 20. Tissue sections were
stained in the same way as cells except that TBS-Tween 20 was used instead of PBS. Rat anti
Ki67 clone TEC3 staining was developed by sequential incubation with the biotinylated sec-
ondary antibody from the rat ABC Staining System (Santa Cruz Biotechnology, Santa Cruz,
CA, USA) at 1:100 and Streptavidin Dylight 488 (Pierce) at 1:200.
For immunohistochemistry on paraffin-embedded tissues, sections were treated in the same
way as for IF, without the Image-iT FX step and the staining was developed using the Imm-
PRESS Peroxydase System (Vector Labs, Peterborough, UK).
Primary antibodies were used at the following concentrations; rabbit anti-Annexin A8
(Eurogentec) 1:100 for tissue and cells; mouse anti-ERα clone 6F11 (Leica Microsystems, Mil-
ton Keynes, UK) 1:70; rat anti-Ki67 clone TEC-3 (Dako) 1:50; goat anti-MCM3 (G19, Santa
Cruz) 1:300; goat anti-mouse SCF R/c-kit (AF1356, R&D Systems Inc., Minneapolis, MN,
USA,) 1:100 for IF. Donkey Alexa Fluor 488- and Alexa Fluor 594-labelled secondary antibod-
ies (Molecular Probes) were used at a dilution 1:1000. For triple-staining, donkey anti-rabbit
Alexa Fluor 488, donkey anti-goat-Cy5, and donkey anti-rat-Cy3 antibodies were used.
For EdU staining, a Click-iT EdU Alexa Fluor 595 Imaging Kit was used as per
manufacturer’s instructions.
Western blotting
Protein extracts were prepared using Triton X-100 lysis buffer plus Complete Protease Inhibi-
tors (Roche Applied Science) and Protein Phosphatase Inhibitor Cocktail 2 (Sigma-Aldrich).
The proteins were separated in NuPAGE 4–12% Bis-Tris gels and transferred to PROTRAN
nitrocellulose transfer membranes (Whatman, Springfield Mill, Maidstone, Kent, UK). Mem-
branes were blocked in 3% BSA diluted in TBS-Tween (20mM Tris pH7.6, 137mMNaCl, 0.1%
Tween-20). The antibodies were diluted in blocking solution and incubated with the mem-
brane in agitation for 2 hours at room temperature or overnight at 4°C and washed with
TBS-Tween before developing with ECLWestern Blotting Detection Reagents (GE Healthcare,
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UK Limited, Little Chalfont, Buckinghamshire, UK) in a FUJIFILM LAS-3000 Intelligent Dark
Box (FUJIFILM UK Ltd, Bedford, UK). Antibodies were used at the following concentrations:
rabbit anti-Annexin A8 (Eurogentec) 1:1000; rabbit anti-Ki67 (Abcam) 1:1000; goat anti-actin
(C-11; Santa Cruz) 1:1000. Anti-goat secondary antibodies conjugated with horseradish perox-
idase (DAKO, Glostrup Denmark) were used at 1:2000. Horseradish peroxidase-conjugated
anti-rabbit IgG secondary antibody (GE Healthcare) was used at 1:5000.
Cell Sorting
Primary mouse mammary cells were isolated by mechanical and enzymatic digestion as described
[38]. Single cell suspensions at 106 cells/ml were stained with anti-CD24-FITC (1.0μg/ml; BD Bio-
sciences, Oxford, UK), anti-Sca-1-APC (1.0μg/ml; eBioscience, Hatfield, UK), anti-CD45-PE-Cy7
(1.0μg/ml; BD Biosciences), anti-CD49f-PE-Cy5 (5.0μl/ml; BD Biosciences) and anti-c-Kit-PE
(1.0μg/ml; BD Biosciences). Cells were sorted on a FACSAria (Becton Dickinson, Oxford, UK) and
mammary stem cells (MaSCs; CD45−, CD24+/Low, Sca-1neg., CD49fHigh, c-Kit−), myoepithelial cells
(CD45− CD24+/Low, Sca-1−, CD49fLow, c-Kit−), luminal epithelial ERα−ve progenitors (CD45−,
CD24+/High, Sca-1−, CD49f−, c-Kit+) and luminal epithelial ERα+ve differentiated cells (CD45−,
CD24+/High, Sca-1+, CD49f−, c-Kit−) isolated using sort gates and controls as described [39].
Freshly sorted normal cells were resuspended in RLT buffer (Qiagen, Crawley, West Sussex,
UK) and stored at −80°C until required for RNA extraction. qPCR reactions were performed as
previously described [40] using TAQMAN Assays-on-Demand probe for Anxa8
(Mm00507926_m1). Actb (β-actin) was used as an endogenous control and results calculated
using the Δ-ΔCt method. Data were expressed as the fold difference in gene expression between
the mean of three independently isolated cell preparations compared to control samples with
95% confidence intervals.
Quantitative RT-PCR on total mammary gland RNA
RNA from mammary glands was prepared using TRIZOL (Invitrogen) as described previously
[35]. The RT reaction was carried out using 1μg of total RNA and Transcriptor reverse tran-
scriptase (Roche Applied Science) following the guidelines of the supplier. For qPCR the fol-
lowing sets of primers and probes (Universal Probe Library from Roche Applied Science) were
used to amplify Anxa8 (ggaaaagcagcagacaggat, gagaactacccttcacgctgac, probe #31) and Krt18
(agatgacaccaacatcacaagg, tccagaccttggacttcctc, probe #78) as internal control. The qPCR was
performed using 1μl of cDNA as template, LC480 QPCRMaster Mix (Roche Applied Science)
and the appropriate set of primers in a 20μl reaction in a LightCycler 480 Instrument (Roche
Applied Science).
Results
ANXA8 is expressed in a distinct subpopulation of luminal ductal
epithelial cells
To obtain an indication towards ANXA8’s role during mammary gland development it was
necessary to assess its cellular distribution at different developmental time points. Since no an-
tibodies were commercially available that recognised mouse ANXA8, a polyclonal antibody
was raised and affinity-purified against full-length mouse ANXA8 protein, which showed spe-
cific reactivity in western blots with mouse ANXA8 but not with other annexins. Immunohis-
tochemistry (IHC) detected ANXA8 protein specifically in a distinct subset of ductal luminal
epithelial cells during puberty, adulthood, and pregnancy, and to a lesser extent in the major
ducts during lactation (Fig. 1, S1 Fig.), while no ANXA8 was detectable in proliferating TEB or
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Fig 1. ANXA8 protein expression during mammary gland development. Sections from pubertal (6
weeks; V6), virgin (12 weeks, V12) pregnant (P, days 4.5, 12.5, 17.5), lactating (day 7) and involuting mice
(days 1, 2, 4, and 10) were stained for ANXA8 protein. Staining was detected in a distinct set of ductal luminal
epithelial cells (arrows), while alveoli (arrowheads) did not stain for ANXA8. ANXA8 was not expressed in the
Annexin A8 in Mammary Gland Epithelium
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alveoli, or in differentiated alveolar epithelium. After enforced involution ANXA8 expression
increased slowly and after four days was widely detected in major ducts and rarely in collapsed
alveoli. After 10 days, ANXA8 was expressed in the majority of surviving ductal epithelial cells,
which was consistent with the increased abundance of AnxA8 mRNA observed by qRT-PCR
post-involution (S2 Fig.). In summary, ANXA8 expression was associated with a subpopula-
tion of luminal ductal epithelial cells and with the surviving ductal epithelium during
involution.
ANXA8 expression is absent in highly proliferative mammary epithelium
Analysis of data from a previous microarray study of pre-pubertal, pubertal and post-pubertal
mouse mammary glands revealed that Anxa8mRNA abundance was highest during pre-pu-
berty and strongly reduced at the onset of puberty (Fig. 2 (A)) [41] when the non-proliferative
rudimentary ducts form proliferative TEB that grow out into the surrounding fat pad to estab-
lish the primary ductal mammary epithelial network. This reduction was confirmed by
early involuting epithelium, but in the major ducts and widely in the surviving epithelium during late involution.
The black bar represents 100μm.
doi:10.1371/journal.pone.0119718.g001
Fig 2. ANXA8 is expressed strongest during pre-puberty. (A) Microarray results from a previous microarray study [41], using RNA extracted from 3-, 4-,
5-, 6- and 7-week old CD1 mice, show a reduction in AnxA8mRNA at the onset of puberty. Signal intensities for two independent probes targeting AnxA8
were normalised to cytokeratin 18 (Krt18) to eliminate changes due to differences in epithelial content. (B) qRT-PCR results for AnxA8 normalised to Krt18
expression from RNA extracted frommammary glands of 3-, 4-, 6-, and 12-week-old mice. (C-D) Immunohistochemical analysis of ANXA8 expression using
the E2R6.2 antibody on mammary glands from 3- (C) and 6-week old (D) mice showing staining for ANXA8 in the pre-pubertal rudiment and in ducts, but not
TEB, of pubertal mice. Negative control (−ve ctrl): no primary antibody. Bars represent 100μm.
doi:10.1371/journal.pone.0119718.g002
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qRT-PCR using mRNA from 3-, 4-, 6-, and 12-week old mice, when normalised to the epitheli-
al cell marker CK18 (Fig. 2(B)). IHC analysis showed again that ANXA8 was expressed in a dis-
tinct subpopulation of luminal epithelial cells of the pre-pubertal rudimentary epithelium
(Fig. 2 (C)), as well as in individual cells of the ductal luminal epithelium in pubertal glands but
never in TEB (Fig. 2 (D)). In contrast, Ki67 expression was widespread in TEB and in prolifer-
ating alveoli during pregnancy but rare in major ducts (S3 Fig.). ANXA8’s association with
non-proliferative cells was further emphasised when 3-week old mice were injected with EdU
for two hours (S4 Fig. (A)). Mammary glands from three independent mice showed no co-
staining for ANXA8 and EdU. Highly proliferative regions, possibly by the onset of puberty,
showed strong EdU staining, but no ANXA8 positivity, while ANXA8+ve ducts showed little
EdU positivity with no overlap. Similar results were found in 4-day involuting glands, where
strong ANXA8 staining but no EdU staining was observed in the surviving ductal epithelium
(S4 Fig. (B)). Our results therefore associate ANXA8 with the low-proliferative rudimentary
ductal epithelium, and show that its expression is switched off during pubertal outgrowth
and proliferation.
ANXA8 expressing epithelial cells are ERα−ve and transiently quiescent
Double-immunofluorescent (IF) labelling of pubertal mammary sections for ANXA8 and Ki67
established that over 99% of ANXA8+ve cells were quiescent with a lack of Ki67 expression
(Fig. 3 (A, B)) and of the licensing factor MCM3 (S5 Fig.). However, the proportion of Ki67+-
ve/ANXA8+ve cells increased significantly during early pregnancy, reaching*15% of all
ANXA8+ve cells (compared to*20% in ANXA8−ve ductal cells) but decreasing again to
*5% during mid-pregnancy (day 12.5), while the proportion of cycling ANXA8−ve cells re-
mained constantly high (*19%; Fig. 3(B)). This demonstrated that ANXA8+ve cells were not
all terminally differentiated, but were able to enter the cell cycle at the start of ductal budding,
though ANXA8 was not detected in the newly formed epithelial structures.
Since it has previously been reported that ERα−ve cells of the mammary epithelium are the
main proliferative compartment, the ERα-status of the ANXA8+ve cells was also established.
Double-IF staining demonstrated that all ANXA8 expressing cells were in fact ERα−ve (Fig. 3 (C,
D)), showing that ANXA8 was associated with a transiently quiescent ERα−ve subpopulation.
AnxA8 mRNA is associated with c-kit+ve/ERα−ve luminal progenitor
cells
ANXA8 is strongly expressed in BRCA1-associated breast cancers and these cancers have re-
cently been shown to originate from ERα−ve luminal progenitor cells [42]. Since ANXA8
showed strong association with ERα−ve cells in the mammary gland it was hypothesised that
ANXA8 was associated with the ERα−ve progenitor cell population. AnxA8mRNA expression
was therefore measured by qRT-PCR in RNA from mammary epithelial cells that had been
sorted according to their expression of the cell surface proteins CD24, CD49f, Sca1, and c-kit:
a) mammary stem cells (MaSC; CD24+/low, Sca1−, CD49f+/high, c-kit−), b) myoepithelial cells
(CD24+/low, Sca1−, CD49f+/low, c-kit−), c) mature luminal ERα+ve cells (CD24+/high, Sca1+,
CD49f−, c-kit−), and ERα−ve luminal progenitor cells (CD24+/high, Sca1−, CD49f−, c-kit+) [39].
While no AnxA8mRNA was detectable in MaSC or myoepithelial cells, the luminal ERα−ve
progenitor cell population had a 17-fold increased abundance compared to the differentiated
luminal ERα+ve population (Fig. 4 (A)). The strong association of ANXA8 and c-kit expres-
sion was further emphasised by IF (Fig. 4 (B, C)). ANXA8 was co-expressed with c-kit in the
luminal epithelium of mammary ducts, and localised to the cytoplasm as well as the apical and,
similar to c-kit, to the lateral membranes (Fig. 4 (C)). However, co-expression of c-kit and
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ANXA8 varied within and between sections. While all ANXA8+ve cells were c-kit+ve indepen-
dent of developmental stage, ANXA8 positivity of c-kit+ve cells ranged from as little as 0% to
100%. During puberty, strong c-kit staining was detected in the inner body cells of the TEB
Fig 3. ANXA8 positive cells are ERα and Ki67 negative. Co-immunofluorescence staining for ANXA8 and Ki67 (A) or ERα (C) in 6-week old mice shows
that those cells strongly positive for ANXA8 are negative for ERα and Ki67. Graphs represent the mean percentage of ANXA8 positive and negative cells that
are positive or negative for Ki67 (B) or ERα (D) based on 1,000 cells per developmental time point (B) and at least 500 cells (D). V6: virgin 6 weeks; P4.5:
pregnancy day 4.5; P12.5: pregnancy day 12.5. Error bars denote standard error of the mean.
doi:10.1371/journal.pone.0119718.g003
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Fig 4. ANXA8 is expressed in ERα−ve/c-kit+ve luminal progenitor cells. (A) Primary mammary epithelial
cells were sorted and RNA extracted as described previously [39]. qRT-PCRwas used to measure AnxA8
mRNA abundance in four different populations. AnxA8 was not detected in either mammary stem cells
(MaSC) or myoepithelial cells. Although very low levels were detected in differentiated ERα+ve luminal
epithelial cells, ERα−ve luminal epithelial progenitor cells showed a 17-fold higher abundance. The graph
shows the abundance relative to the levels of expression in differentiated cells and 95% confidence limits. (B)
Bar graph showing the proportion of c-kit+ve/AnxA8+ve and c-kit+ve/AnxA8−ve cells during puberty (V6),
early (P4.5) and late (P12.5) pregnancy. 1,000 cells were assessed per developmental time point. Error Bars
denote standard error of the mean. (C) Co-immunofluorescence staining for ANXA8 and c-kit in mouse
mammary gland from an early-pregnant (day 4.5) mouse.
doi:10.1371/journal.pone.0119718.g004
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while ANXA8 could only be found in the ductal epithelium (S6 Fig.). During pregnancy
ANXA8 and c-kit expression were both restricted to the ductal epithelium, though limited c-
kit staining was found in the newly formed ductal outgrowth. The percentage of ANXA8+ve/c-
kit+ve positive cells was reduced during pregnancy from just*62% to*34% (Fig. 4 (B)), pos-
sibly reflecting the overall reduction in ANXA8+ve cells as c-kit was still expressed in the ma-
jority of ductal luminal epithelial cells.
Triple-staining of mammary glands from pubertal and mid-pregnant mice further con-
firmed that ANXA8+ve/c-kit+ve cells were mostly Ki67−ve (Fig. 5). Our results therefore
strongly suggest that ANXA8 is associated with a subpopulation of mostly quiescent c-kit+-
ve/ERα−ve ductal luminal progenitor cells.
ANXA8 over expression reduces proliferation in Kim-2 cells
Since ANXA8 expression was associated with low proliferation in the mammary gland and
other tissues [43,44], in vitro studies were carried out to assess whether ANXA8 could directly
affect cell proliferation. Mouse ANXA8 was over expressed in the mouse mammary epithelial
cell line Kim-2, using an inducible episomal vector under the control of doxycycline (dox)
(Kim2A8). Approximately 50% of the pooled cells expressed ANXA8 and EGFP through a bi-
directional promoter when treated with 100ng/ml dox (S7 Fig.). Since only EGFP-positive cells
expressed ANXA8, EGFP-positivity was used as a surrogate marker for ANXA8 expression in
further experiments.
Microscopic analysis after dox-treatment showed that after two days the EGFP+ve cells
were increased in size (Fig. 6 (A)) compared to EGFP−ve cells, and after six days showed a
highly enlarged and flattened morphology (Fig. 6 (B)) with significantly enlarged nuclei (Fig. 6
(C)). Although this morphology was reminiscent of senescent cells, the cells were negative for
the senescence markers β-galactosidase (β-gal) and p16 (data not shown).
A cell growth assay of Kim2A8 cells showed that after three days of dox-treatment Kim2A8
cell growth was significantly reduced compared to control cells (Fig. 7 (A)). Since the decreased
growth rate was associated with reduced BrdU incorporation (Fig. 7 (B)) our results showed
that in this system ANXA8 over-expression was able to reduce cell proliferation.
ANXA8 over expression prevents colony formation of Kim-2 cells in vitro
To further characterise the effect of ANXA8 over expression on cell proliferation, a 2D colony
formation assay was performed. Kim2A8 and control cells were seeded as single cell suspen-
sions and treated with or without dox. Colonies were analysed by bright-field and fluorescence
microscopy. After two weeks of dox-treatment Kim2A8 cells formed significantly fewer colo-
nies of more than 50 cells compared to untreated Kim2A8 cells or control cells (Fig. 7 (C, D)).
All large colonies that formed from the dox-treated Kim2A8 cells were largely EGFP−ve (with
the occasional entrapped green cell), and hence did not express ANXA8. EGFP+ve cells re-
mained either as single cells or very small colonies of<10 cells, and showed again the above
mentioned enlarged morphology (S8 Fig.).
ANXA8 over expression induces quiescence in Kim-2 cells
FACS analysis was performed after 48 hours with or without dox-treatment to further assess
the nature of the growth arrest induced by ANXA8 expression in Kim2A8 cells (Fig. 8 (A)).
Dox-treated Kim2A8 cells showed a significantly higher proportion of cells in G0/G1 (75%) com-
pared to untreated Kim2A8 cells (59%) or the negative control cells (52% −dox; 54%+dox),
while the amount of Kim2A8 cells in S- or G2/M-phase was strongly reduced (S-phase: −dox:
16%; +dox:<8%; G2/M: −dox:23% vs +dox:15%), demonstrating an arrest at G0/G1. No increase
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Fig 5. ANXA8+ve/c-kit+ve luminal progenitor cells are mostly Ki67−ve. Co-immunofluorescence staining for ANXA8 (green), c-kit (red), and Ki67
(purple) in mouse mammary gland from virgin and mid-pregnant mice shows that ANXA8+ve cells express c-kit, but not Ki67. The Ki67 staining has been
coloured purple for easier visualisation in the triple-merged image. These are representative images of at least three independent mice for each time point.
doi:10.1371/journal.pone.0119718.g005
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Fig 6. ANXA8 expression inducesmorphological changes in Kim-2 cells. Kim2A8 and Kim2RTS cells were grown in the presence or absence of
100ng/ml dox. Pictures were taken after 48 hours (A) or six days (B) of treatment. EGFP was used as a reporter of ANXA8 expression. Both proteins are
expressed from opposite sides of a bidirectional promoter. (C) Nuclear sizes were analysed after 6 days by measuring the nuclear area (stained with DAPI) of
at least 90 individual cells from each dox-treated and untreated populations using ImageJ. There was a significant difference between Kim2A8 cells
expressing and not expressing ANXA8 (ANOVA: p<0.05).
doi:10.1371/journal.pone.0119718.g006
Fig 7. ANXA8 expression inhibits proliferation of Kim2A8 cells. (A) Kim2A8 and Kim2RTS cells were seeded in 24-well plates, allowed to attach and
grown in the presence or absence of 100ng/ml dox (first treatment at time point 0). At each time point protein extracts were prepared (in duplicates). The
graph shows the amount of protein as determined by BCA assay against time. This assay was performed in triplicate and the graph shows a representative
result from one experiment. (B) Cells were seeded in 96-well plates and treated with dox for 48 hours, labelled with BrdU and the incorporation of BrdU was
quantified and plotted for each condition (six wells per condition). ***p< 0.001 (C) Equal amount of cells (250–300) were grown in the presence or absence
of 100ng/ml dox. After 14 days cells were fixed, stained and the plates photographed. A representative plate per condition is shown. The experiment was
carried out in triplicate. (D) Graph showing the number of colonies per plate from the experiment (C) as quantified by Image J (**p<0.003).
doi:10.1371/journal.pone.0119718.g007
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Fig 8. ANXA8 expression arrests Kim2A8 cells in G0. (A) Kim2A8 and Kim2RTS cells were grown in 6-well plates with or without 100ng/ml of dox for 48
hours. The graph shows the average percentage numbers of cells in G0/G1, S and G2/M as quantified by FACS from three independent experiments. (B)
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in the sub-G0/G1 fraction was observed (all between 1–1.5%), confirming that ANXA8 over ex-
pression did not induce cell death.
To establish whether ANXA8 over expressing cells were arrested in G1 or entered G0, we
measured Ki67 expression levels by IF staining (Fig. 8 (B, C)) and western blot (Fig. 8 (D)). IF
staining showed that only*50% of EGFP-positive Kim2A8 cells expressed Ki67, while nearly
all EGFP negative cells, like the control cells, were Ki67 positive (*95%; p<0.003). In western
blots untreated cells and dox-treated control cells showed similar levels of Ki67 protein, while
over expression of ANXA8 for 6 days significantly reduced Ki67 protein levels by*50%. This
demonstrated that ANXA8 over expression had taken KIM-2 cells out of the cell cycle.
Discussion
We previously described Anxa8 mRNA to be expressed in isolated mammary ducts and after
enforced involution, but not during pregnancy and lactation when primary ducts branch and
bud to form milk secreting alveoli [45]. The current study further defines ANXA8 expression
in a mostly quiescent subpopulation of c-kit+ve/ERα−ve progenitor cells of the ductal epitheli-
um, and identifies ANXA8 as a potential regulator of proliferation and/or quiescence in the
mouse mammary ductal epithelium. No significant levels of AnxA8 expression were found in
ERα+ve cells, or in differentiated alveoli of late pregnant or lactating mice (Figs. 1, and 3),
showing that ANXA8 expression was not associated with terminal differentiation of the mam-
mary epithelium. Instead, ANXA8 was only present in the major ducts, which bud during preg-
nancy to form alveoli, and was widespread in the ducts of a late involuting gland, when
apoptosis had ceased and the primary mammary ductal system was regenerating.
Although a large proportion of c-kit+ve cells showed ANXA8 expression by double-IF
staining, not all of them did, and as ANXA8 and Ki67 staining were largely exclusive it appears
that ANXA8 may be characteristic of a mostly quiescent subpopulation of committed ERα−ve
progenitor cells, which our triple-staining supports. However, rare Ki67+ve/ANXA8+ve cells
could be detected (less than 1% of all ANXA8+ve cells) during puberty and this proportion in-
creased at the start of pregnancy, but decreased again with prolonged pregnancy while Ki67
staining of ductal ANXA8−ve cells remained increased. Therefore, although ANXA8 express-
ing cells were mostly quiescent, these cells were not terminally differentiated. It is unclear
whether the progeny of the ANXA8+ve cells contribute to the formation of side branches and
alveoli. No ANXA8 staining was found in alveoli and c-kit staining was equally down-regulat-
ed. Though AnxA8mRNA was recently detected in quiescent normal human mammary stem
cells isolated from mammosphere cultures on the basis of PKH26-retention [46], we could not
detect ANXA8 in mouse mammary stem cells. An association with very early mammary epi-
thelial progenitor cells is supported by the recent finding that AnxA8mRNA is expressed in
the early developing mammary bud epithelium (E12.5) which showed limited proliferation
and expressed c-kit [47], though in contrast to c-kit we were not able to detect ANXA8 protein
by IHC at this time point (data not shown).
A recent finding that ANXA8 is part of the ADAM-17/AREG shedding complex and can
modulate the shedding of pro-amphiregulin and other EGF family members on the cell surface
[48], and the finding that ANXA8 affects ligand-induced degradation of EGFR [31] raises the
Kim2A8 and Kim2RTS cells grown in chamber slides with or without 100ng/ml dox for six days were fixed and stained for Ki67 antigen. EGFP was used as a
reporter of ANXA8 expression. (C) Graph showing the percentage of Ki67-positivity in the EGFP positive and negative populations of Kim2A8 cells grown
with or without 100ng/ml dox. At least 1000 cells were analyzed in each population. (D) Western blot showing Ki67 and ANXA8 protein expression in cells
after six days in culture. Actin was used as a loading control. Numbers show the relative intensities of ANXA8 and Ki67 bands respectively (normalised to
actin) determined by measuring area pixel intensities using AIDA Image Analyzer software. The reduction of Ki67 levels (*50%) is consistent with the
reduced number of Ki67+ve Dox-treated Kim2A8 cells seen in (B).
doi:10.1371/journal.pone.0119718.g008
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attractive possibility that ANXA8 may directly affect ligand availability for growth factor recep-
tors and/or signalling, thereby controlling cell growth and/or differentiation. Since ADAM17
has also been shown to be a major sheddase for c-kit [49] and growth factor ligands including
kit-ligand [50] it is tempting to speculate that ANXA8 may directly affect c-kit signalling in the
luminal progenitors of the mammary gland. It was also noticeable that the number of ANXA8
positive cells varied greatly between ductal areas in a gland and between glands of similar time
points. Whether ANXA8+ve cells mark the sites of future secondary/tertiary branches is cur-
rently subject of further investigations using a lineage tracing approach.
Our current data are further consistent with other studies that have linked AnxA8 expres-
sion to reduced proliferative activity and/or quiescence. When quiescent NIH3T3 fibroblasts
were driven into proliferation by transduction with an adenoviral E2F1 construct Anxa8 was
one of the strongest down-regulated genes in two independent experiments [51]. Similar re-
sults for Anxa8 were obtained when NIH3T3 cells were transfected with Nanog, leading to in-
creased proliferation and transformation and a reduction in AnxA8mRNA [52]. In the fetal
bovine growth plate ANXA8 expression forms a gradient in which the higher expression is
found in the low-proliferative hypertrophic zone [44], while in adult mouse stratified epithelia
ANXA8 is expressed in supra-basal layers, suggesting that ANXA8 expression may be associat-
ed with partial differentiation [43], though our own studies identified ANXA8 in Ki67−ve cells
of the basal layer (data not shown). Further, since ANXA8 expression was not detected in dif-
ferentiating alveolar cells during pregnancy or lactation it is highly unlikely to be associated
with differentiation in the mammary gland.
Despite AnxA8mRNA up-regulation early during involution, ANXA8 protein could not be
detected in the early collapsing alveoli and therefore was unlikely to be involved in apoptosis,
as our microarray profile may have suggested. Involution can be induced through forced wean-
ing of the pups at the height of lactation, leading to widespread alveolar cell death and tissue re-
modeling, after which the mammary gland resembles a pre-pregnant-like mammary gland.
Transcriptional microarray profiling identified Anxa8mRNA to be strongly increased 24
hours after enforced mammary gland involution with sustained abundance for several days
[29], though our qRT-PCR data now show a much slower increase. Similar increases can be
found for c-kit and the kit ligand SCF (S9 Fig.), indicating that the involution recovery involves
c-kit+ve progenitor cells and/or leads to a relative increase in c-kit+ve cells due to a preferential
loss of differentiated alveolar cells. ANXA8 protein was not detected in the apoptotic alveoli 48
hours after enforced weaning (Fig. 1, S1 Fig.), but was detectable in major ducts and in most of
the surviving epithelium after 10 days. Neither could ANXA8 be found in TEB during puberty
where apoptosis is prevalent during ductal lumen formation [53,54]. Our view that ANXA8 is
not associated with cell death is further supported by our finding that ANXA8 over expression
in Kim-2 cells did not induce cell death, as indicated by no change in the sub-G1 fraction after
ANXA8 over expression (Fig. 8). There was though some expression of ANXA8 in the col-
lapsed epithelial structures 4 days after forced weaning when most apoptosis has already ceased
and tissue remodeling with an immune response and suppressed inflammation occurs
[35,55,56]. It cannot be ruled out that ANXA8 expression in these structures may be associated
with its PLA2 inhibitory activity described for many annexins, including ANXA8 [17], thereby
supporting the inflammatory suppression described previously [35,56].
Several annexins, including annexins A1 [10,57], A2 [58,59] and A6 [60,61] have been
found to modulate proliferation or to be directly involved in cell division, including annexin
A11, which is part of and necessary for midbody formation during cytokinesis [5]. Inhibition
of proliferation induced by ANXA1 and ANXA6 correlated with concomitant changes in the
actin cytoskeleton and cell morphology. ANXA8 has previously been found to interact with F-
actin in co-sedimentation assays and with PIP2, suggesting that ANXA8 may play a role in the
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regulation of actin/membrane interactions [62]. However, we did not detect any changes in the
actin cytoskeletal structure in Kim2A8 cells (data not shown). The morphological changes we
observed were similar to those reported for ANXA2 over-expression in MIOMüller cells [63],
in which ANXA2 expression induced the cells to become flattened, but the increase in the size
of the footprint observed did not correlate with an increase in cellular volume when analysed
by FACS. It has also been demonstrated that over expression of ANXA8 in SCK, MDA-MB231
and NIH3T3 cells can induce morphological changes, inducing a more epithelial-like morphol-
ogy, and that these changes may be mediated through direct interaction of ANXA8 with FAK
[23].
ANXA8’s reduced expression in the majority of breast cancers is consistent with an anti-
proliferative role of ANXA8. However, the finding that positive staining correlates with basal-
like breast cancers that are of high grade and positive for Ki67 [29] is somewhat counterintui-
tive. Similar results have been described for the tumour suppressor protein p16/INK4, which is
associated with cell cycle arrest and senescence, but is strongly associated with basal-like breast
cancers [64]. Further, the cell cycle protein cyclin E has been shown to induce cell cycle arrest
by p27KIP accumulation in mammary epithelial cell lines HC-11 and 184B5, though it in-
creased proliferation in others [65,66] and is strongly expressed in basal-like breast cancers
[67]. Since c-kit+ve/ERα−ve luminal progenitor cells have recently been shown to be the origin
of basal-like breast cancers [42,68], and since ANXA8 is strongly associated with this subgroup,
it is possible that ANXA8 expression in these cancers is a reflection of ANXA8’s close associa-
tion with luminal progenitor cells, and that the pro-quiescence function of ANXA8 might be
perturbed. A similar association of ANXA8 with committed human progenitor cells and cancer
had previously been found in the haematopoietic system, where AnxA8mRNA expression was
detected in pro-myelocytes and was further up-regulated in APL [69], a leukaemia in which
the c-kit+ve progenitor cell population is abnormal and expanded. AnxA8 was specifically up-
regulated in APL but not in other myelocytic leukaemias [18,19,69]. Treatment with ATRA
down-regulated ANXA8 expression and pushed cells into differentiation [19]. Though a causal
link between ANXA8 down-regulation and differentiation of APL cells has not been tested it is
tempting to speculate that ANXA8 might be involved in progenitor cell maintenance. Further
studies will reveal whether the same association exists between the ANXA8+ve cells of the ter-
minal duct lobular unit [29] and c-kit in the human breast.
Given our results and the association of ANXA8 expression with ER−ve breast cancers it
will be worth testing whether ANXA8 over-expression in ER+ve breast cancer cell lines can in-
duce cellular quiescence or reduce proliferation. However, as the human genome contains at
least two Anxa8 genes (Anxa8, Anxa8l1), which vary slightly in their encoding sequence, and
in the absence of promoter expression studies, epigenetic analyses and human genotyping, it is
impossible to know which one (if not both) of these genes contributes to the variations ob-
served in gene expression in the normal and malignant breast. The existence of copy number
and allelic population variants could further affect gene product "dosage" as well as the phar-
macogenetic responsiveness of these genes [70]. Therefore, over-expression of each variant on
its own and in combination in a variety of breast cancer cell lines will be necessary.
Conclusion
We have established for the first time that ANXA8 expression is associated with a subpopula-
tion of transiently quiescent c-kit+ve/ERα−ve cells of the ductal epithelium and that ANXA8
over expression can induce quiescence in vitro. The mechanism(s) by which ANXA8 induces
this G0-arrest is still unknown. Its expression is therefore strongly associated with a luminal ep-
ithelial progenitor cell population that is thought to be the origin of basal-like breast cancers, a
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subgroup of breast cancers with which ANXA8 is strongly associated. Further work will estab-
lish whether ANXA8 is functionally involved in progenitor cell quiescence and/or mainte-
nance, and whether ANXA8 positive mammary epithelial cells may be the origin of ANXA8-
expressing basal-like breast cancers.
Supporting Information
S1 Fig. ANXA8 protein expression during mammary gland development. Close-up view of
images from Fig. 1. The black bar represents 100μm.
(TIF)
S2 Fig. qRT-PCR results for AnxA8 from 13 stages of mammary gland development. Total
RNA was extracted from mammary glands at the indicated time points and tested for presence
of Anxa8 mRNA by qRT-PCR. Results are shown in relation to Krt 18 mRNA abundance.
(TIF)
S3 Fig. ANXA8 and Ki67 expression in TEB, ducts, and during early pregnancy. Immuno-
histochemical staining for ANXA8 and Ki67 of consecutive mammary tissue sections of the
same TEB and duct region from the same 3-, and 5-week C57BL/6 old pubertal mice, and from
an early pregnant mouse (day 4.5) shows that areas of ANXA8 and Ki67 expression are largely
exclusive. Magnification x100.
(TIF)
S4 Fig. ANXA8 expression in EdU labelled mammary glands. Double-immunofluorescent
labelling for ANXA8 (green) and EdU (red) shows that ANXA8+ve cells are EdU−ve in pre-
puberty and during involution. Mouse mammary glands have been in vivo labelled for 2 hours
in pre-pubertal mice (3 weeks of age) (A), and 4 days after forced weaning (B) before culling.
(A) Top two rows show examples of mammary ducts with high ANXA8-staining but little EdU
staining in the mammary epithelium, while the bottom row shows a typical TEB with high
EdU-staining but no ANXA8 staining. (B) At 4 days of involution mammary glands showed
no epithelial EdU incorporation, but widespread ANXA8 expression. Top two rows show two
epithelial ducts, while the bottom row shows positive EdU staining in lymphocytes of the ingui-
nal lymph node (pos. control). Bars represent 50μm.
(TIF)
S5 Fig. ANXA8 positive cells are negative for MCM3. Co-immunofluorescence staining for
ANXA8 and MCM3 in 6-week old C57BL/6 mice shows that those cells strongly positive for
ANXA8 are MCM3−ve. Bars represent 50μm.
(TIF)
S6 Fig. Co-expression of ANXA8 and c-kit protein. Co-immunofluorescence staining for
ANXA8 (red), and c-kit (green) in a mouse mammary gland from a 6-week old virgin (V6)
and a 12-day pregnant (P12.5) adult mouse showing that while all ANXA8+ve cells express c-
kit, only a subgroup of c-kit+ve cells express ANXA8. Bars represent 50μm.
(TIF)
S7 Fig. Kim2A8 cells express ANXA8 and EGFP after dox induction. (A) Kim2A8 cells were
grown in chamber slides with 100ng/ml dox for 24 hours, fixed and stained with E2R6.2 anti-
body to detect ANXA8 expression. EGFP was co-expressed by a bi-directional promoter. All
EGFP positive cells expressed ANXA8, so that EGFP positivity could be used as a reporter for
ANXA8 expression in this cell line. (B) Kim2A8 and Kim2RTS cells were grown in the pres-
ence of 100ng/ml of dox for 5 days and ANXA8 protein levels measured in dox-treated and
Annexin A8 in Mammary Gland Epithelium
PLOSONE | DOI:10.1371/journal.pone.0119718 March 24, 2015 20 / 24
un-treated cells. Actin was used as a loading control.
(TIF)
S8 Fig. Colony formation of ANXA8 over-expressing Kim2 cells is suppressed. Kim2A8
cells were grown for two weeks in the presence of 100ng/ml dox as described in Fig. 7(C). Sin-
gle cells or small colonies (<20 cells) of EGFP-positive Kim2A8 cells were detected after two
weeks of growth. These cells showed a flat, large and round morphology. Images of typical col-
onies from Kim2A8 cells with or without dox treatment are shown.
(TIF)
S9 Fig. RNA expression of c-kit, SCF and AnxA8 during enforced involution.Microarray re-
sults from lactating (day 7) and involuting (days 1, 2, 3, 4, 20) mouse mammary glands from a
previous study [35]. The graphs show the normalized average signal intensities for AnxA8, c-
kit, and scf/kit ligandmRNAs ±standard error.
(TIF)
Acknowledgments
The authors would like to thank Prof Barry Gusterson for helpful advice, financial support and
critical discussions. They would also like to thank Drs J. Stingl, A. Michie, C. Huser, E. Cosimo,
D. Olijnyk, Mr J. Kennedy and Ms M. Vukovic for technical assistance as well as helpful discus-
sions and advice. Further, they would like to thank Prof. C. Watson for the Kim-2 cell line and
Dr. B. Howard for providing embryonic mammary bud sections.
Author Contributions
Conceived and designed the experiments: JMI MJS TS KB. Performed the experiments: JMI
CJC RKF LM KS HKMAP TS. Analyzed the data: JMI KS HKMJS KB TS. Contributed re-
agents/materials/analysis tools: JMI FMMJS KB TS. Wrote the paper: JMI ROM TS.
References
1. Morgan RO, Martin-Almedina S, Garcia M, Jhoncon-Kooyip J, Fernandez MP. Deciphering function
and mechanism of calcium-binding proteins from their evolutionary imprints. Biochim Biophys Acta.
2006; 1763: 1238–1249. PMID: 17092580
2. Liu J, Vishwanatha JK. Regulation of nucleo-cytoplasmic shuttling of human annexin A2: a proposed
mechanism. Mol Cell Biochem. 2007; 303: 211–220. PMID: 17457518
3. Lin CY, Jeng YM, Chou HY, Hsu HC, Yuan RH, et al. Nuclear localization of annexin A1 is a prognostic
factor in oral squamous cell carcinoma. J Surg Oncol. 2008; 97: 544–550. doi: 10.1002/jso.20992
PMID: 18297688
4. Rick M, Ramos Garrido SI, Herr C, Thal DR, Noegel AA, et al. Nuclear localization of Annexin A7 during
murine brain development. BMC Neurosci. 2005; 6: 25. PMID: 15819996
5. Tomas A, Futter C, Moss SE. Annexin 11 is required for midbody formation and completion of the termi-
nal phase of cytokinesis. J Cell Biol. 2004; 165: 813–822. PMID: 15197175
6. Hayes MJ, Rescher U, Gerke V, Moss SE. Annexin-actin interactions. Traffic 2004; 5: 571–576. PMID:
15260827
7. Moss SE, Morgan RO. The annexins. Genome Biol. 2004; 5: 219 PMID: 15059252
8. Morgan RO, Martin-Almedina S, Iglesias JM, Gonzalez-Florez MI, Fernandez MP. Evolutionary per-
spective on annexin calcium-binding domains. Biochim Biophys Acta. 2004; 1742: 133–140. PMID:
15590063
9. Rescher U, Gerke V. Annexins—unique membrane binding proteins with diverse functions. J Cell Sci.
2004; 117: 2631–2639. PMID: 15169834
10. Ang EZ-F, Nguyen HT, Sim H-L, Putti TC, Lim LHK. Annexin-1 regulates growth arrest induced by high
levels of estrogen in MCF-7 breast cancer cells. Mol Cancer Res. 2009; 7: 266–274. doi: 10.1158/
1541-7786.MCR-08-0147 PMID: 19208747
Annexin A8 in Mammary Gland Epithelium
PLOSONE | DOI:10.1371/journal.pone.0119718 March 24, 2015 21 / 24
11. Raynal P, Pollard HB, Srivastava M. Cell cycle and post-transcriptional regulation of annexin expres-
sion in IMR-90 human fibroblasts. Biochem J. 1997; 322 (Pt 2): 365–371.
12. Schlaepfer DD, Haigler HT. Expression of annexins as a function of cellular growth state. J Cell Biol.
1990; 111: 229–238. PMID: 2142163
13. de Graauw M, van Miltenburg MH, Schmidt MK, Pont C, Lalai R, et al. Annexin A1 regulates TGF-beta
signaling and promotes metastasis formation of basal-like breast cancer cells. Proc Natl Acad Sci U S
A. 107: 6340–6345. doi: 10.1073/pnas.0913360107 PMID: 20308542
14. Fatimathas L, Moss SE. Annexins as disease modifiers. Histol Histopathol. 2010; 25: 527–532 PMID:
20183805
15. Hayes MJ, Moss SE. Annexin 2 has a dual role as regulator and effector of V-Src in cell transformation
J Biol Chem. 2009; 284: 10202–10210. doi: 10.1074/jbc.M807043200 PMID: 19193640
16. Gonzalo DH, Lai KK, Shadrach B, Goldblum JR, Bennett AE, et al. Gene expression profiling of serrat-
ed polyps identifies annexin A10 as a marker of a sessile serrated adenoma/polyp. J Pathol. 2013; 230:
420–429. doi: 10.1002/path.4200 PMID: 23595865
17. Hauptmann R, Maurer-Fogy I, Krystek E, Bodo G, Andree H, et al. Vascular anticoagulant beta: a novel
human Ca2+/phospholipid binding protein that inhibits coagulation and phospholipase A2 activity. Its
molecular cloning, expression and comparison with VAC-alpha. Eur J Biochem. 1989; 185: 63–71.
PMID: 2530088
18. Chang KS, Wang G, Freireich EJ, Daly M, Naylor SL, et al. Specific expression of the annexin VIII gene
in acute promyelocytic leukemia. Blood. 1992; 79: 1802–1810. PMID: 1313714
19. Hu ZB, MaW, Uphoff CC, Drexler HG. Expression and modulation of annexin VIII in human leukemia-
lymphoma cell lines. Leukemia Res. 1993; 17: 949–957. PMID: 8231235
20. Liu JH, Stass SA, Chang KS. Expression of the annexin VIII gene in acute promyelocytic leukemia.
Leukemia Lymphoma. 1994; 13: 381–386. PMID: 8069182
21. Sarkar A, Yang P, Fan YH, Mu ZM, Hauptmann R, et al. Regulation of the expression of annexin VIII in
acute promyelocytic leukemia. Blood. 1994; 84: 279–286. PMID: 8018923
22. Karanjawala Z, Illei P, Ashfaq R, Infante J, Murphy K, et al. NewMarkers of Pancreatic Cancer Identi-
fied Through Differential Gene Expression Analyses: Claudin 18 and Annexin A8. Am J Surg Pathol.
2008; 32: 188–196. doi: 10.1097/PAS.0b013e31815701f3 PMID: 18223320
23. Lee M-J, Yu G-R, Yoo H-J, Kim J-H, Yoon B-I, et al. ANXA8 Down-regulation by EGF-FOXO4 Signaling
Is Involved in Cell Scattering and Tumor Metastasis of Cholangiocarcinoma. Gastroenterology. 2009;
137: 1138–1150. doi: 10.1053/j.gastro.2009.04.015 PMID: 19376120
24. Singhal S, Wiewrodt R, Malden LD, Amin KM, Matzie K, et al. Gene expression profiling of malignant
mesothelioma. Clin Cancer Res. 2003; 9: 3080–3097. PMID: 12912960
25. Jaeger J, Koczan D, Thiesen H-J, Ibrahim SM, Gross G, et al. Gene expression signatures for tumor
progression, tumor subtype, and tumor thickness in laser-microdissected melanoma tissues. Clin Can-
cer Res. 2007; 13: 806–815. PMID: 17289871
26. Chao A, Wang T-H, Lee Y-S, Hsueh S, Chao A-S, et al. Molecular characterization of adenocarcinoma
and squamous carcinoma of the uterine cervix using microarray analysis of gene expression. Int J Can-
cer. 2006; 119: 91–98. PMID: 16450401
27. Wang S, Zhan M, Yin J, Abraham JM, Mori Y, et al. Transcriptional profiling suggests that Barrett's
metaplasia is an early intermediate stage in esophageal adenocarcinogenesis. Oncogene. 2006; 25:
3346–3356. PMID: 16449976
28. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. Molecular portraits of human breast tu-
mours. Nature. 2000; 406: 747–752. PMID: 10963602
29. Stein T, Price KN, Morris JS, Heath VJ, Ferrier RK, et al. Annexin A8 is up-regulated during mouse
mammary gland involution and predicts poor survival in breast cancer. Clin Cancer Res. 2005; 11:
6872–6879. PMID: 16203777
30. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, et al. Repeated observation of breast tumor sub-
types in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003; 100: 8418–8423.
PMID: 12829800
31. Goebeler V, Poeter M, Zeuschner D, Gerke V, Rescher U. Annexin A8 Regulates Late Endosome Or-
ganization and Function. Mol Biol Cell. 2008; 19: 5267–5278. doi: 10.1091/mbc.E08-04-0383 PMID:
18923148
32. Poeter M, Brandherm I, Rossaint J, Rosso G, Shahin V, et al. Annexin A8 controls leukocyte recruit-
ment to activated endothelial cells via cell surface delivery of CD63. Nat Commun. 2014; 5: 3738. doi:
10.1038/ncomms4738 PMID: 24769558
Annexin A8 in Mammary Gland Epithelium
PLOSONE | DOI:10.1371/journal.pone.0119718 March 24, 2015 22 / 24
33. Adachi K, Toyota M, Sasaki Y, Yamashita T, Ishida S, et al. Identification of SCN3B as a novel p53-in-
ducible proapoptotic gene. Oncogene. 2004; 23: 7791–7798. PMID: 15334053
34. Osada M, Park HL, Nagakawa Y, Begum S, Yamashita K, et al. A novel response element confers p63-
and p73-specific activation of the WNT4 promoter. Biochem Biophys Res Commun. 2006; 339: 1120–
1128. PMID: 16343436
35. Stein T, Morris JS, Davies CR, Weber-Hall SJ, Duffy M-A, et al. Involution of the mouse mammary
gland is associated with an immune cascade and an acute-phase response, involving LBP, CD14 and
STAT3. Breast Cancer Res. 2004; 6: R75–91. PMID: 14979920
36. Gordon KE, Binas B, Chapman RS, Kurian KM, Clarkson RW, et al. A novel cell culture model for study-
ing differentiation and apoptosis in the mouse mammary gland. Breast Cancer Res. 2000; 2: 222–235.
PMID: 11056687
37. BornkammGW, Berens C, Kuklik-Roos C, Bechet JM, Laux G, et al. Stringent doxycycline-dependent
control of gene activities using an episomal one-vector system. Nucleic Acids Res. 2005; 33: e137.
PMID: 16147984
38. Smalley MJ. Isolation, culture and analysis of mouse mammary epithelial cells. In: Ward A, Tosh D, edi-
tors. Methods Mol Biol. New York: Springer; 2010. pp. 139–170. doi: 10.1007/978-1-60761-756-3_9
PMID: 20700710
39. Regan JL, Kendrick H, Magnay FA, Vafaizadeh V, Groner B, et al. c-Kit is required for growth and sur-
vival of the cells of origin of Brca1-mutation-associated breast cancer. Oncogene. 2012; 31: 869–883.
doi: 10.1038/onc.2011.289 PMID: 21765473
40. Kendrick H, Regan JL, Magnay FA, Grigoriadis A, Mitsopoulos C, et al. Transcriptome analysis of mam-
mary epithelial subpopulations identifies novel determinants of lineage commitment and cell fate. BMC
Genomics. 2008; 9: 591. doi: 10.1186/1471-2164-9-591 PMID: 19063729
41. McBryan J, Howlin J, Kenny PA, Shioda T, Martin F. ERalpha-CITED1 co-regulated genes expressed
during pubertal mammary gland development: implications for breast cancer prognosis. Oncogene.
2007; 26: 6406–6419. PMID: 17486082
42. Molyneux G, Geyer FC, Magnay FA, McCarthy A, Kendrick H, et al. BRCA1 basal-like breast cancers
originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell. 2010; 7:
403–417. doi: 10.1016/j.stem.2010.07.010 PMID: 20804975
43. Runkel F, Michels M, Franken S, Franz T. Specific expression of annexin A8 in adult murine stratified
epithelia. J Mol Histol. 2006; 37: 353–359. PMID: 17082908
44. White AH, Watson REB, Newman B, Freemont AJ, Wallis GA. Annexin VIII is differentially expressed
by chondrocytes in the mammalian growth plate during endochondral ossification and in osteoarthritic
cartilage. J Bone Miner Res. 2002; 17: 1851–1858. PMID: 12369789
45. Stein T, Price KN, Morris JS, Heath VJ, Ferrier RK, et al. Annexin A8 is up-regulated during mouse
mammary gland involution and predicts poor survival in breast cancer. Clin Cancer Res. 2005; 11:
6872–6879. PMID: 16203777
46. Pece S, Tosoni D, Confalonieri S, Mazzarol G, Vecchi M, et al. Biological and molecular heterogeneity
of breast cancers correlates with their cancer stem cell content. Cell. 2010; 140: 62–73. doi: 10.1016/j.
cell.2009.12.007 PMID: 20074520
47. Wansbury O, Mackay A, Kogata N, Mitsopoulos C, Kendrick H, et al. Transcriptome analysis of embry-
onic mammary cells reveals insights into mammary lineage establishment. Breast Cancer Res. 2011;
13: R79. doi: 10.1186/bcr2928 PMID: 21834968
48. Nakayama H, Fukuda S, Inoue H, Nishida-Fukuda H, Shirakata Y, et al. Cell surface-annexins regulate
ADAM-mediated ectodomain shedding of proamphiregulin. Mol Biol Cell. 2012.
49. Cruz AC, Frank BT, Edwards ST, Dazin PF, Peschon JJ, et al. Tumor necrosis factor-alpha-converting
enzyme controls surface expression of c-Kit and survival of embryonic stem cell-derived mast cells. J
Biol Chem. 2004; 279: 5612–5620. PMID: 14625290
50. Kawaguchi N, Horiuchi K, Becherer JD, Toyama Y, Besmer P, et al. Different ADAMs have distinct in-
fluences on Kit ligand processing: phorbol-ester-stimulated ectodomain shedding of Kitl1 by ADAM17
is reduced by ADAM19. J Cell Sci. 2007; 120: 943–952. PMID: 17344430
51. Ma Y, Croxton R, Moorer RL, CressWD. Identification of novel E2F1-regulated genes by microarray.
Arch Biochem Biophys. 2002; 399: 212–224. PMID: 11888208
52. Piestun D, Kochupurakkal BS, Jacob-Hirsch J, Zeligson S, Koudritsky M, et al. Nanog transforms
NIH3T3 cells and targets cell-type restricted genes. Biochem Biophys Res Commun. 2006; 343: 279–
285. PMID: 16540082
53. Humphreys RC. Programmed cell death in the terminal endbud. J Mammary Gland Biol Neoplasia.
1999; 4: 213–220. PMID: 10426400
Annexin A8 in Mammary Gland Epithelium
PLOSONE | DOI:10.1371/journal.pone.0119718 March 24, 2015 23 / 24
54. Humphreys RC, Krajewska M, Krnacik S, Jaeger R, Weiher H, et al. Apoptosis in the terminal endbud
of the murine mammary gland: a mechanism of ductal morphogenesis. Development. 1996; 122:
4013–4022. PMID: 9012521
55. Stein T, Salomonis N, Gusterson BA. Mammary gland involution as a multi-step process. J Mammary
Gland Biol Neoplasia. 2007; 12: 25–35. PMID: 17431797
56. Clarkson RW,Wayland MT, Lee J, Freeman T, Watson CJ. Gene expression profiling of mammary
gland development reveals putative roles for death receptors and immune mediators in post-lactational
regression. Breast Cancer Res. 2004; 6: R92–109. PMID: 14979921
57. Alldridge LC, Bryant CE. Annexin 1 regulates cell proliferation by disruption of cell morphology and inhi-
bition of cyclin D1 expression through sustained activation of the ERK1/2 MAPK signal. Exp Cell Res.
2003; 290: 93–107. PMID: 14516791
58. Chiang Y, Rizzino A, Sibenaller ZA, Wold MS, Vishwanatha JK. Specific down-regulation of annexin II
expression in human cells interferes with cell proliferation. Mol Cell Biochem. 1999; 199: 139–147.
PMID: 10544962
59. Inokuchi J, Narula N, Yee DS, Skarecky DW, Lau A, et al. Annexin A2 positively contributes to the ma-
lignant phenotype and secretion of IL-6 in DU145 prostate cancer cells. Int J Cancer. 2009; 124: 68–74.
doi: 10.1002/ijc.23928 PMID: 18924133
60. Monastyrskaya K, Babiychuk EB, Hostettler A, Wood P, Grewal T, et al. Plasmamembrane-associated
annexin A6 reduces Ca2+ entry by stabilizing the cortical actin cytoskeleton. J Biol Chem. 2009; 284:
17227–17242. doi: 10.1074/jbc.M109.004457 PMID: 19386597
61. Theobald J, Smith PD, Jacob SM, Moss SE. Expression of annexin VI in A431 carcinoma cells sup-
presses proliferation: a possible role for annexin VI in cell growth regulation. Biochim Biophys Acta.
1994; 1223: 383–390. PMID: 7918674
62. Goebeler V, Ruhe D, Gerke V, Rescher U. Annexin A8 displays unique phospholipid and F-actin bind-
ing properties. FEBS Lett. 2006; 580: 2430–2434. PMID: 16638567
63. Hayes MJ, Shao D, Bailly M, Moss SE. Regulation of actin dynamics by annexin 2. EMBO J. 2006; 25:
1816–1826. PMID: 16601677
64. Bohn OL, Fuertes-Camilo M, Navarro L, Saldivar J, Sanchez-Sosa S. p16INK4a expression in basal-
like breast carcinoma. Int J Clin Exp Pathol. 2010; 3: 600–607. PMID: 20661408
65. Sgambato A, Han EK, Zhou P, Schieren I, Weinstein IB. Overexpression of cyclin E in the HC11 mouse
mammary epithelial cell line is associated with growth inhibition and increased expression of p27(Kip1).
Cancer Res. 1996; 56: 1389–1399. PMID: 8640830
66. Sgambato A, Doki Y, Schieren I, Weinstein IB. Effects of cyclin E overexpression on cell growth and re-
sponse to transforming growth factor beta depend on cell context and p27Kip1 expression. Cell Growth
Differ. 1997; 8: 393–405. PMID: 9101085
67. Bostrom P, SoderstromM, Palokangas T, Vahlberg T, Collan Y, et al. Analysis of cyclins A, B1, D1 and
E in breast cancer in relation to tumour grade and other prognostic factors. BMC Res Notes. 2009; 2:
140. doi: 10.1186/1756-0500-2-140 PMID: 19615042
68. Lim E, Vaillant F, Wu D, Forrest NC, Pal B, et al. Aberrant luminal progenitors as the candidate target
population for basal tumor development in BRCA1mutation carriers. Nat Med. 2009; 15: 907–913. doi:
10.1038/nm.2000 PMID: 19648928
69. Payton JE, Grieselhuber NR, Chang LW, Murakami M, Geiss GK, et al. High throughput digital quantifi-
cation of mRNA abundance in primary human acute myeloid leukemia samples. J Clin Invest. 2009;
119: 1714–1726. doi: 10.1172/JCI38248 PMID: 19451695
70. Uddin M, Thiruvahindrapuram B, Walker S, Wang Z, Hu P, et al. A high-resolution copy-number varia-
tion resource for clinical and population genetics. Genet Med. 2014. doi: 10.1038/gim.2014.178
Annexin A8 in Mammary Gland Epithelium
PLOSONE | DOI:10.1371/journal.pone.0119718 March 24, 2015 24 / 24
